203 related articles for article (PubMed ID: 25908103)
41. Linker phosphorylation of Smad3 promotes fibro-carcinogenesis in chronic viral hepatitis of hepatocellular carcinoma.
Murata M; Yoshida K; Yamaguchi T; Matsuzaki K
World J Gastroenterol; 2014 Nov; 20(41):15018-27. PubMed ID: 25386050
[TBL] [Abstract][Full Text] [Related]
42. Genetic polymorphisms in the Wnt/β-catenin pathway genes as predictors of tumor development and survival in patients with hepatitis B virus-associated hepatocellular carcinoma.
Kim SS; Cho HJ; Lee HY; Park JH; Noh CK; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
Clin Biochem; 2016 Jul; 49(10-11):792-801. PubMed ID: 26968103
[TBL] [Abstract][Full Text] [Related]
43. Soluble angiogenesis factors in sera of Egyptian patients with hepatitis C virus infection: correlation with disease severity.
Talaat RM
Viral Immunol; 2010 Apr; 23(2):151-7. PubMed ID: 20373995
[TBL] [Abstract][Full Text] [Related]
44. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis?
Hammad LN; Abdelraouf SM; Hassanein FS; Mohamed WA; Schaalan MF
J Immunotoxicol; 2013; 10(4):380-6. PubMed ID: 23350952
[TBL] [Abstract][Full Text] [Related]
45. Genetic variants associated with the progression of hepatocellular carcinoma in hepatitis C Egyptian patients.
Motawi TK; Shaker OG; Ismail MF; Sayed NH
Gene; 2013 Sep; 527(2):516-20. PubMed ID: 23845776
[TBL] [Abstract][Full Text] [Related]
46. Aberrant expression of p-STAT3 in peripheral blood CD4+ and CD8+ T cells related to hepatocellular carcinoma development.
Wang X; Xin W; Zhang H; Zhang F; Gao M; Yuan L; Xu X; Hu X; Zhao M
Mol Med Rep; 2014 Nov; 10(5):2649-56. PubMed ID: 25175640
[TBL] [Abstract][Full Text] [Related]
47. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma.
Shin HS; Kim SU; Park JY; Kim DY; Han KH; Chon CY; Baatarkhuu O; Ahn SH
J Gastroenterol Hepatol; 2012 Sep; 27(9):1528-34. PubMed ID: 22497450
[TBL] [Abstract][Full Text] [Related]
48. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
[TBL] [Abstract][Full Text] [Related]
49. Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma.
Wang D; Luo L; Chen W; Chen LZ; Zeng WT; Li W; Huang XH
Oncol Rep; 2014 Mar; 31(3):1199-204. PubMed ID: 24366206
[TBL] [Abstract][Full Text] [Related]
50. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C.
Squadrito G; Cacciola I; Alibrandi A; Pollicino T; Raimondo G
J Hepatol; 2013 Oct; 59(4):696-700. PubMed ID: 23751755
[TBL] [Abstract][Full Text] [Related]
51. The Prognostic Value of Circulating VEGF-A Level in Patients With Hepatocellular Cancer.
Lacin S; Yalcin S
Technol Cancer Res Treat; 2020; 19():1533033820971677. PubMed ID: 33234055
[TBL] [Abstract][Full Text] [Related]
52. Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis.
Ren Y; Poon RT; Tsui HT; Chen WH; Li Z; Lau C; Yu WC; Fan ST
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5996-6001. PubMed ID: 14676125
[TBL] [Abstract][Full Text] [Related]
53. Low serum interleukin-6 levels as a predictive marker of recurrence in patients with hepatitis B virus related hepatocellular carcinoma who underwent curative treatment.
Cho HJ; Kim SS; Ahn SJ; Park SY; Park JH; Kim JK; Wang HJ; Cheong JY; Cho SW
Cytokine; 2015 Jun; 73(2):245-52. PubMed ID: 25797190
[TBL] [Abstract][Full Text] [Related]
54. Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma.
Park Y; Park Y; Lim HS; Kim YS; Hong DJ; Kim HS
Tissue Antigens; 2012 Feb; 79(2):97-103. PubMed ID: 22136460
[TBL] [Abstract][Full Text] [Related]
55. Type II ground-glass hepatocytes as a marker of hepatocellular carcinoma in chronic hepatitis B.
Mathai AM; Alexander J; Kuo FY; Torbenson M; Swanson PE; Yeh MM
Hum Pathol; 2013 Aug; 44(8):1665-71. PubMed ID: 23574780
[TBL] [Abstract][Full Text] [Related]
56. Serum interleukin-6 and interferon-gamma levels in patients with hepatitis B-associated chronic liver disease.
Tangkijvanich P; Vimolket T; Theamboonlers A; Kullavanijaya P; Suwangool P; Poovorawan Y
Asian Pac J Allergy Immunol; 2000 Jun; 18(2):109-14. PubMed ID: 10928624
[TBL] [Abstract][Full Text] [Related]
57. Gene expression profiling of hepatitis B- and hepatitis C-related hepatocellular carcinoma using graphical Gaussian modeling.
Ueda T; Honda M; Horimoto K; Aburatani S; Saito S; Yamashita T; Sakai Y; Nakamura M; Takatori H; Sunagozaka H; Kaneko S
Genomics; 2013 Apr; 101(4):238-48. PubMed ID: 23485556
[TBL] [Abstract][Full Text] [Related]
58. TNF-α and IL-10 polymorphisms increase the risk to hepatocellular carcinoma in HCV infected individuals.
Aroucha DC; Carmo RF; Vasconcelos LR; Lima RE; Mendonça TF; Arnez LE; Cavalcanti Mdo S; Muniz MT; Aroucha ML; Siqueira ER; Pereira LB; Moura P; Pereira LM; Coêlho MR
J Med Virol; 2016 Sep; 88(9):1587-95. PubMed ID: 26890368
[TBL] [Abstract][Full Text] [Related]
59. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.
Mazzaferro V; Romito R; Schiavo M; Mariani L; Camerini T; Bhoori S; Capussotti L; Calise F; Pellicci R; Belli G; Tagger A; Colombo M; Bonino F; Majno P; Llovet JM;
Hepatology; 2006 Dec; 44(6):1543-54. PubMed ID: 17133492
[TBL] [Abstract][Full Text] [Related]
60. IL17A gene polymorphisms, serum IL-17A and IgE levels, and hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.
Li N; Zhu Q; Li Z; Han Q; Zhang G; Chen J; Lv Y; Xing F; Chen Y; Zeng X; Liu Z
Mol Carcinog; 2014 Jun; 53(6):447-57. PubMed ID: 23280722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
